Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Should FDA Drug Safety Alerts Go To Professionals First?

Executive Summary

Physicians need to know about drug safety problems before their patients hear about them, Steven Schachter, president of the American Epilepsy Society, told the FDA Transparency Task Force June 24
Advertisement

Related Content

PhRMA Wants FDA To Explain When Decisions Depart From Committee Votes
Sharfstein Heads FDA Transparency Task Force
FDA Issues Suicidality Alert On Antiepileptics
FDA Issues Suicidality Alert On Antiepileptics
FDA To Continue Providing Emerging Safety Info, But Not Through Drug Watch

Topics

Advertisement
UsernamePublicRestriction

Register

PS051249

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel